Screener
USANA Health Sciences USNA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by USANA Health Sciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: USANA Health Sciences’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:35 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000896264-26-000034
| Line item | Three months ended / April 4,2026 | Three months ended / March 29,2025 |
|---|---|---|
| Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets | ||
| Cash and cash equivalents | $162,751 | $179,613 |
| Restricted cash included in other assets | 2,906 | 2,754 |
| Total cash, cash equivalents, and restricted cash | $165,657 | $182,367 |
| Supplemental disclosures of cash flow information | ||
| Cash paid during the period for: | ||
| Interest | $242 | $52 |
| Income taxes | 9,111 | 7,767 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is USANA Health Sciences's cash & equivalents?
- USANA Health Sciences (USNA) reported cash & equivalents of $165.66M in Q1 2026.
- How has USANA Health Sciences's cash & equivalents changed year-over-year?
- USANA Health Sciences's cash & equivalents decreased by 9.2% year-over-year, from $182.37M to $165.66M.
- What is the long-term trend for USANA Health Sciences's cash & equivalents?
- Over 5 years (2020 to 2025), USANA Health Sciences's cash & equivalents has grown at a -12.7% compound annual growth rate (CAGR), from $311.92M to $158.38M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about USANA Health Sciences's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude